The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. German American Bancorp Inc (GABC) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.But making German American Bancorp Inc an even more interesting and timely stock to look at, is the fact that in trading on Monday, shares of GABC entered into oversold territory, changing hands as low as $32.675 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In the case of German American Bancorp Inc, the RSI reading has hit 21.3 — by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 57.7. A falling stock price — all else being equal — creates a better opportunity for dividend investors to capture a higher yield. Indeed, GABC's recent annualized dividend of 0.76/share (currently paid in quarterly installments) works out to an annual yield of 1.55% based upon the recent $49.19 share price. A bullish investor could look at GABC's 21.3 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on GABC is its dividend history. In general, dividends are not always predictable; but, looking at the history chart below can help in judging whether the most recent dividend is likely to continue.
HOST // Robert Powell
Retirement Planning Event
More from Stocks
Biogen May Shed $18 Billion in Value After Scrapping Alzheimer's Drug Trial
Biogen shares plunge Thursday, wiping nearly $20 billion in value from the biotech group, after it dropped a late-stage trial for a key Alzheimer's disease drug.
Apple Shares Grind Higher Amid Multiple Upgrades Ahead of March 25 Launch Event
Apple shares rises after three analysts' upgrades for the world's biggest tech company ahead of its much-anticipated launch event next week in Cupertino.
How to Buy Gold: Six Tips and Reasons to Buy in 2019
Buying gold is easier than you may think - but you have to do your homework first.
Powell and Company Can Influence the Macro, but Not the Micro
All the money in the world cannot change the fact that rising stock prices and falling earnings make the market more expensive.